Skip to main content

Table 2 In vitro antiplasmodial activity of the prepared SLNs

From: In vitro evaluation of chloroquine-loaded and heparin surface-functionalized solid lipid nanoparticles

Samples D6 IC50 (based on gross weight of SLNs) D6 IC50 (based on actual CQ concentration at 25 and 21% DL for CQ-SLN and CQ-Hep-SLN) D6 IC50 (Based on actual CQ concentration at 25 and 21% DL and in vitro drug release at 66 h for CQ-SLN (80%) and CQ-Hep-SLN (50%) W2 IC50
Heparin Na salt > 100 µg/mL > 100 µg/mL
SLN > 100 µg/mL > 100 µg/mL
CQ-SLN 23.75 ± 3.24 ng/mL 5.94 ± 0.18 ng/mL 4.752 ± 0.144 ng/mL > 400 ng/mL
Hep-SLN 12.98 ± 1.62 µg/mL   > 100 µg/mL
CQ-Hep-SLN 22.97 ± 2.58 ng/mL 4.82 ± 0.54 ng/mL 2.41 ± 0.27 ng/mL > 400 ng/mL
CQ drug 5.81 ± 0.18 ng/mL 5.81 ± 0.18 ng/mL 5.81 ± 0.18 ng/mL 58.71 ± 2.67 ng/mL